Biogen (BIIB) PT Lowered to $272 at Cantor Fitzgerald
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $216.12 +3.04%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 6 | New: 18
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 6 | New: 18
Join SI Premium – FREE
Cantor Fitzgerald lowered its price target on Biogen (NASDAQ: BIIB) to $272.00 (from $289.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen expects $164M R&D charge to hit Q2 2026 earnings
- FactSet Research Systems (FDS) PT Raised to $253 at Jefferies
- CrowdStrike (CRWD) PT Lowered to $169 at Barclays Post Stock Split
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
